Unit : KRW trillion
Toward a World-Class Innovative Drug Developer
- 5 or more innovative new drugs by 2030
- Enhanced the quality of new drug pipeline
- Invest over USD 250mil in annual R&D
- Strengthening of Open innovation
- Diabetes, metabolic diseases, cancer, autoimmune diseases
- Expand new drug pipelines in clinical development stage
-
Explore Research Preclinical Clinical
- Accelerate clinical developments and business growth worldwide
- New tasks for global clinical development
- Continued growth of AVEO's oncology business in the US
- Diabetes & Metabolism
- Oncology & Immunology
- Cell Therapy
- Vaccine
- Aesthetic
-
Preclinical(4)
-
LR19023
해당 프로젝트 팝업 Molecule LR19023 Stage Preclinical Indication Oncology Modality Cell therapy Target Undisclosed -
LR19128
해당 프로젝트 팝업 Molecule LR19128 Stage Preclinical Indication Oncology Modality Biologics Target Undisclosed Partner Avactar Life sciences Affimer® Technology
-
LR20061
해당 프로젝트 팝업 Molecule LR20061 Stage Preclinical Indication Atopic Dermatitis Modality Chemical Target Undisclosed -
LR19157
해당 프로젝트 팝업 Molecule LR19157 Stage Preclinical Indication Oncology Modality Chemical Target Undisclosed
-
-
Phase I(9)
-
LR19129
해당 프로젝트 팝업 Molecule CUE-102 Stage Phase 1 (by Partner) Location summary USA Indication Oncology Modality Biologics Target WT-1 Partner Cue Biopharma -
LR19127
해당 프로젝트 팝업 Molecule CUE-101 Stage Phase 1 (by Partner) Location summary USA Indication HNSCC Modality Biologics Target HPV Partner Cue Biopharma -
LR19125
해당 프로젝트 팝업 Molecule PDC*Lung Stage Phase 1 (by Partner) Location summary Europe Indication NSCLC Modality Cell therapy Target Cancer vaccine Partner PDC*line Pharma -
LR20011
해당 프로젝트 팝업 Molecule GEN-001 Stage Phase 1 (by Partner) Location summary USA Indication Solid tumor Modality Microbiome Target Microbiome Partner Genome & Company -
AV-380
해당 프로젝트 팝업 Molecule AV-380 Stage Preclinical Location summary USA Indication Cachexia Modality Biologics Target anti-GDF15 IgG1 mAb -
AV-203
해당 프로젝트 팝업 Molecule AV-203 Stage Phase 1 Location summary USA Indication Oncology Modality Biologics Target Anti-ERBB3 IgG1 mAb -
LR19155
해당 프로젝트 팝업 Molecule LR19155 Stage Phase 1 Indication Oncology Modality Biologics Target LILRB1 -
LR19123
해당 프로젝트 팝업 Molecule LC542019 Stage Phase 1 Location summary USA Indication Diabetes Modality NCE Target GPR120 -
LR19018
해당 프로젝트 팝업 Molecule LG203003 Stage Phase 1 Location summary USA Indication NASH Modality NCE Target DGAT-2
-
-
Phase II(5)
-
LR20062
해당 프로젝트 팝업 Molecule aP vaccine Stage Phase 2 Indication aP vaccine Modality Vaccine Target aP vaccine Diphtheria, Tetanus, Pertussis,Polio, Hib, HebB
-
LR19021
해당 프로젝트 팝업 Molecule LB54640 Stage Phase 2 Location summary USA Indication Genetic Obesity Modality NCE Target MC4R -
LR19114
해당 프로젝트 팝업 Molecule 6 in 1 Vaccine Stage Phase 2 Indication 6 in 1 Vaccine Modality Vaccine Target 6 in 1 Vaccine Diphtheriae (D), Bordetella pertussis (wP), Clostridium tetani (T), Hepatitis B (HepB) Haemophilus influenzae type b(Hib) Vaccine-Associated Paralytic Poliomyelitis(IPV)
-
LR19019
해당 프로젝트 팝업 Molecule Zectivimod Stage Phase 2 (by Partner) Location summary China Indication Ulcerative colitis Atopic dermatitis Modality NCE Target S1P1 Partner TransThera (License-out) License-out, China
-
LR19024
해당 프로젝트 팝업 Molecule LG34053 Stage Phase 1b/2 Location summary Republic of Korea Indication Osteoarthritis Modality NCE Target Undisclosed
-
-
Phase III(3)
-
LR19074
해당 프로젝트 팝업 Molecule Tigulixostat Stage Phase 3 Indication Gout Modality NCE Target XO Xanthine Oxidate -
TiNivo-2
해당 프로젝트 팝업 Molecule Tivozanib +/- Nivolumab Stage Phase 3 Location summary Global Indication Renal Cell Carcinoma following prior CPI Modality Small molecule Target VEGFR TKI Partner Bristol Myers Squibb Opdivo combination -
AV-299
해당 프로젝트 팝업 Molecule Ficlatuzumab Stage Phase 3 Location summary Global Indication Head and neck squamous cell carcinoma Modality Biologics Target Anti-HGF/c-MET IgG1 mAb
-
-
NDA(2)
-
LR20024
해당 프로젝트 팝업 Molecule Y-solution, MDR Stage NDA Location summary Europe Indication HA filler Modality HA Target HA -
LR19094
해당 프로젝트 팝업 Molecule Y-solution, China Stage NDA Location summary China Indication HA filler Modality HA Target HA
-